Safety and efficacy of COVID-19 vaccines in patients on dialysis: a multicentre cohort study in Italy
- PMID: 37490271
- DOI: 10.1007/s40620-023-01708-7
Safety and efficacy of COVID-19 vaccines in patients on dialysis: a multicentre cohort study in Italy
Erratum in
-
Correction to: Safety and efficacy of COVID-19 vaccines in patients on dialysis: a multicentre cohort study in Italy.J Nephrol. 2024 Jan;37(1):259-260. doi: 10.1007/s40620-023-01864-w. J Nephrol. 2024. PMID: 38114883 No abstract available.
Abstract
Background: The aim of this study was to evaluate the efficacy and safety of COVID-19 vaccines in patients undergoing haemodialysis in Italy compared to the general population.
Methods: In this cohort study, 118 dialysis centres from 18 Italian Regions participated. Individuals older than 16 years on dialysis treatment for at least 3 months, who provided informed consent were included. We collected demographic and clinical information, as well as data on vaccination status, hospitalisations, access to intensive care units and adverse events. We calculated the incidence, hospitalisation, mortality, and fatality rates in the vaccinated dialysis cohort, adjusted for several covariates. The incidence rates of infection in the dialysis cohort and the general population were compared through Standardised Incidence Rate Ratio.
Results: The study included 6555 patients vaccinated against SARS-CoV-2 infection according to the schedule recommended in Italy. Between March 2021 and May 2022, there were 1096 cases of SARS-CoV-2 infection, with an incidence rate after completion of the three-dose vaccination cycle of 37.7 cases per 100 person-years. Compared to the general population, we observed a 14% reduction in the risk of infection for patients who received three vaccine doses (Standardised Incidence Rate Ratio: 0.86; 95% Confidence Interval: 0.81-0.91), whereas no statistically significant differences were found for COVID-19-related hospitalisations, intensive care unit admissions or death. No safety signals emerged from the reported adverse events.
Conclusions: The vaccination program against SARS-CoV-2 in the haemodialysis population showed an effectiveness and safety profile comparable to that seen in the general population.
Keywords: COVID vaccines; Cohort study; Dialysis; Effectiveness; Safety.
© 2023. The Author(s) under exclusive licence to Italian Society of Nephrology.
References
-
- Levin A, Tonelli M, Bonventre J et al (2017) Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet 390:1888–1917. https://doi.org/10.1016/S0140-6736(17)30788-2 - DOI - PubMed
-
- Jager KJ, Kovesdy C, Langham R et al (2019) A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases. Kidney Int 96:1048–1050. https://doi.org/10.1016/j.kint.2019.07.012 - DOI - PubMed
-
- de Nicola L, Donfrancesco C, Minutolo R et al (2015) Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008–12 National Health Examination Survey. Nephrol Dial Transplant 30:806–814. https://doi.org/10.1093/NDT/GFU383 - DOI - PubMed
-
- Report 2010 – Ridt. https://ridt.sinitaly.org/2017/03/21/report-2010/ . Accessed 22 Sept 2022
-
- Jager KJ, Kramer A, Chesnaye NC et al (2020) Results from the ERA-EDTA registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. https://doi.org/10.1016/j.kint.2020.09.006 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous